A detailed history of Balyasny Asset Management LLC transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Balyasny Asset Management LLC holds 2,189,276 shares of OCUL stock, worth $24.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,189,276
Previous 218,293 902.91%
Holding current value
$24.9 Million
Previous $2.03 Million 1163.8%
% of portfolio
0.04%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$9.09 - $13.6 $17.9 Million - $26.8 Million
1,970,983 Added 902.91%
2,189,276 $25.6 Million
Q2 2025

Aug 14, 2025

BUY
$6.02 - $9.46 $857,392 - $1.35 Million
142,424 Added 187.72%
218,293 $2.03 Million
Q1 2025

May 15, 2025

SELL
$5.93 - $9.08 $128,586 - $196,890
-21,684 Reduced 22.23%
75,869 $556,000
Q4 2024

Feb 14, 2025

BUY
$8.33 - $11.47 $812,616 - $1.12 Million
97,553 New
97,553 $833,000
Q4 2023

Feb 14, 2024

BUY
$2.08 - $4.52 $76,244 - $165,685
36,656 Added 70.03%
89,000 $396,000
Q3 2023

Nov 14, 2023

BUY
$3.14 - $5.04 $12,754 - $20,472
4,062 Added 8.41%
52,344 $164,000
Q2 2023

Aug 14, 2023

BUY
$4.6 - $7.64 $147,972 - $245,763
32,168 Added 199.63%
48,282 $249,000
Q1 2023

May 15, 2023

SELL
$2.79 - $6.27 $24,766 - $55,658
-8,877 Reduced 35.52%
16,114 $84,000
Q4 2022

Feb 14, 2023

BUY
$2.61 - $4.41 $65,226 - $110,210
24,991 New
24,991 $70,000
Q2 2022

Aug 15, 2022

BUY
$3.01 - $5.22 $55,561 - $96,355
18,459 New
18,459 $74,000
Q1 2022

May 16, 2022

SELL
$4.83 - $7.35 $52,704 - $80,203
-10,912 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$6.16 - $12.07 $67,217 - $131,707
10,912 New
10,912 $76,000
Q2 2021

Aug 16, 2021

SELL
$13.43 - $19.16 $224,334 - $320,048
-16,704 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$15.82 - $22.11 $264,257 - $369,325
16,704 New
16,704 $274,000

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $875M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.